Nature Communications (Dec 2018)
Targeting the Mycobacterium ulcerans cytochrome bc 1 :aa 3 for the treatment of Buruli ulcer
- Nicole Scherr,
- Raphael Bieri,
- Sangeeta S. Thomas,
- Aurélie Chauffour,
- Nitin Pal Kalia,
- Paul Schneide,
- Marie-Thérèse Ruf,
- Araceli Lamelas,
- Malathy S. S. Manimekalai,
- Gerhard Grüber,
- Norihisa Ishii,
- Koichi Suzuki,
- Marcel Tanner,
- Garrett C. Moraski,
- Marvin J. Miller,
- Matthias Witschel,
- Vincent Jarlier,
- Gerd Pluschke,
- Kevin Pethe
Affiliations
- Nicole Scherr
- Swiss Tropical and Public Health Institute
- Raphael Bieri
- Swiss Tropical and Public Health Institute
- Sangeeta S. Thomas
- Lee Kong Chian School of Medicine, Nanyang Technological University
- Aurélie Chauffour
- CR7, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC Université Paris 06
- Nitin Pal Kalia
- Lee Kong Chian School of Medicine, Nanyang Technological University
- Paul Schneide
- BASF SE
- Marie-Thérèse Ruf
- Swiss Tropical and Public Health Institute
- Araceli Lamelas
- Swiss Tropical and Public Health Institute
- Malathy S. S. Manimekalai
- School of Biological Sciences, Nanyang Technological University
- Gerhard Grüber
- School of Biological Sciences, Nanyang Technological University
- Norihisa Ishii
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases
- Koichi Suzuki
- Department of Mycobacteriology, Leprosy Research Center, National Institute of Infectious Diseases
- Marcel Tanner
- Swiss Tropical and Public Health Institute
- Garrett C. Moraski
- Department of Chemistry and Biochemistry, Montana State University
- Marvin J. Miller
- Department of Chemistry and Biochemistry, University of Notre Dame
- Matthias Witschel
- BASF SE
- Vincent Jarlier
- CR7, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), Sorbonne Universités, UPMC Université Paris 06
- Gerd Pluschke
- Swiss Tropical and Public Health Institute
- Kevin Pethe
- Lee Kong Chian School of Medicine, Nanyang Technological University
- DOI
- https://doi.org/10.1038/s41467-018-07804-8
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 9
Abstract
Mycobacterium ulcerans is the causative agent of Buruli ulcer (BU). Existing anti-tubercular drugs have been used to treat the condition with varying success. Here, the authors show that a clinical-stage drug candidate for tuberculosis, Q203, is effective at killing M. ulcerans and is a promising therapeutic candidate for BU.
